Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Harvard Apparatus Regenerative Technology, Inc.

Ticker
HRGN
Sector
Industry
Report date
November 13, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

There is no recent news specifically about Harvard Apparatus Regenerative Technology, Inc. in the provided business news. The company’s latest SEC filings provide the most current insights into its financial and operational status.

Recent developments:
  • No recent business news articles directly related to Harvard Apparatus Regenerative Technology, Inc. were identified in the provided recent news business dataset [N1].
Overview

Harvard Apparatus Regenerative Technology, Inc. operates in a business environment characterized by recurring losses and an accumulated deficit. The company generates product revenue but incurs substantial operating expenses, including research and development and general administrative costs. The company’s financial position as of late 2025 and Q3 2026 shows limited liquidity with current liabilities exceeding current assets, though cash and cash equivalents provide some coverage. The company has performance-based stock compensation arrangements that have not yet resulted in recognized expense due to milestone achievement uncertainty. The company’s financial statements include a going concern disclosure, indicating reliance on additional financing to sustain operations. Insider trading policies are in place to ensure compliance with applicable laws and regulations.

Executive summary

Harvard Apparatus Regenerative Technology, Inc. is a company with detailed audited financial disclosures through its 2025 Annual Report (10-K) and 2026 Q3 Quarterly Report (10-Q). The company has recurring operating losses and an accumulated deficit, with product revenues reported but operating expenses significantly exceeding revenues. The company’s financial statements include a going concern note highlighting substantial doubt about its ability to continue without additional financing. As of September 30, 2026, liquidity ratios indicate current liabilities exceed current assets, though cash and cash equivalents exceed current liabilities on a cash ratio basis. The company has unvested performance-based stock options with significant unrecognized compensation expense. Recent news coverage does not provide direct updates on the company’s operations or financials. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for HRGN

Bull case model:

The company has demonstrated some revenue growth from 2024 to 2025 and maintains cash and cash equivalents that exceed current liabilities on a cash ratio basis as of Q3 2026. The presence of performance-based stock options suggests potential future value creation contingent on milestone achievements. The company’s ongoing efforts in research and development may support future product development.

Bear case model:

The company has recurring operating losses and an accumulated deficit, with operating expenses significantly exceeding revenues. Liquidity ratios indicate current liabilities exceed current assets, raising concerns about short-term financial stability. The going concern disclosure highlights substantial doubt about the company’s ability to continue without additional financing. Unrecognized compensation expense related to performance-based awards adds to potential future financial obligations.

Moat:

The available information does not provide explicit details on competitive advantages or proprietary technology that would constitute a moat. The company’s financial disclosures focus on operational and financial challenges rather than unique market positioning or barriers to entry.

Risks overview
Risks summary
The primary risk is the company’s substantial doubt about its ability to continue as a going concern due to recurring losses and liquidity constraints, necessitating additional financing to sustain operations.
Risks details:

• Going Concern Risk: The company’s financial statements include a going concern note citing recurring losses, accumulated deficit, and the need for additional financing, which raises substantial doubt about its ability to continue operations without new funding [S1].
• Liquidity Risk: As of September 30, 2026, the company’s current liabilities exceed current assets, resulting in a current ratio below 1.0, indicating potential challenges in meeting short-term obligations [S2].
• Performance-Based Compensation Risk: The company has significant unvested performance-based stock options with unrecognized compensation expense of approximately $3.3 million, which could impact future financial results depending on milestone achievement [S1].

FINAL FORECAST FOR HRGN

Final take one line
Harvard Apparatus Regenerative Technology, Inc. exhibits very high visibility with detailed audited financial disclosures highlighting operational challenges and liquidity risks.
Final take 12 to 24 month view

Business trends: The company continues to report recurring operating losses and an accumulated deficit, with limited revenue growth and ongoing research and development expenses.
Execution milestones: Achievement of performance-based stock option milestones and securing additional financing are critical for sustaining operations.
Key risks: Liquidity constraints, going concern uncertainties, and potential financial impact from unrecognized compensation expenses pose significant risks.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Harvard Apparatus Regenerative Technology, Inc. is a company that has recurring losses from operations and an accumulated deficit as of the latest filings [S1].
  • The company prepares consolidated financial statements audited by CBIZ CPAs P.C. and previously by Marcum LLP [S1].
  • As of December 31, 2025, the company had total assets of approximately $2.7 million and total liabilities of approximately $1.6 million, resulting in stockholders' equity of about $1.1 million [S1].
  • The company had product revenue of $704,000 in 2025, up from $430,000 in 2024, but incurred operating losses of $6.9 million in 2025 [S1].
  • Operating expenses include cost of sales, research and development, sales and marketing, and general and administrative expenses [S1].
  • The company has unvested performance-based stock options with unrecognized compensation expense of approximately $3.3 million as of December 31, 2025 [S1].
  • The company’s consolidated financial statements have been prepared assuming it will continue as a going concern, but there is substantial doubt about its ability to continue without additional financing [S1].
  • As of September 30, 2026, the company had cash and cash equivalents of approximately $1.85 million and current assets of about $2.3 million, with current liabilities of about $2.65 million, resulting in a current ratio of 0.87 and a cash ratio of 1.15 [S2].
  • The company reported a net loss of approximately $1.46 million for the three months ended September 30, 2026, with basic earnings per share of -$0.08 [S2].
  • The company’s insider trading policy is designed to promote compliance with insider trading laws and listing standards [S1].
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-19 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | 3 Dividend Stocks That Raised Their Payouts Through Both 2008 and 2020 | https://www.nasdaq.com/articles/3-dividend-stocks-raised-their-payouts-through-both-2008-and-2020
  • N2 | 2026-11-13 | www.nasdaq.com | INNOVATE (VATE) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/innovate-vate-q3-2026-earnings-call-transcript
  • N3 | 2026-11-13 | www.nasdaq.com | NeoVolta (NEOV) Q1 2027 Earnings Call Transcript | https://www.nasdaq.com/articles/neovolta-neov-q1-2027-earnings-call-transcript
  • N4 | 2026-11-13 | www.nasdaq.com | Snail Inc (SNAL) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/snail-inc-snal-q3-2026-earnings-call-transcript
  • N5 | 2026-11-13 | www.nasdaq.com | Verrica (VRCA) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/verrica-vrca-q3-2026-earnings-call-transcript
  • N6 | 2026-11-13 | www.nasdaq.com | PEDEVCO (PED) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/pedevco-ped-q3-2026-earnings-call-transcript
  • N7 | 2026-11-13 | www.nasdaq.com | Central Puerto (CEPU) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/central-puerto-cepu-q3-2026-earnings-call-transcript
  • N8 | 2026-11-13 | www.nasdaq.com | Cohen & Co. (COHN) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/cohen-co-cohn-q3-2026-earnings-call-transcript
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine